Latest Articles
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - PR Newswire
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting PR Newswire
Published: April 24, 2024, 7 a.m.
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting - Investor Relations | Karyopharm Therapeutics
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting Investor Relations | Karyopharm Therapeutics
Published: April 24, 2024, 7 a.m.
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer - Cancer Health Treatment News
Novel ADC and Immunotherapy Combo Shows Promise for Endometrial Cancer Cancer Health Treatment News
Published: April 9, 2024, 7 a.m.
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer - OncLive
Dr Porter on Mirvetuximab Soravtansine Plus Pembrolizumab in FRα+ pMMR/MSS Endometrial Cancer OncLive
Published: April 8, 2024, 7 a.m.
Pennington Biomedical: Raising awareness of endometrial cancer - Greater Baton Rouge Business Report
Pennington Biomedical: Raising awareness of endometrial cancer Greater Baton Rouge Business Report
Published: April 8, 2024, 7 a.m.
Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer - Li - 2024 - Advanced Science - Wiley Online Library
Phosphorylation of IDH1 Facilitates Progestin Resistance in Endometrial Cancer - Li - 2024 - Advanced Science Wiley Online Library
Published: April 6, 2024, 7 a.m.
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer - OncLive
Differentiating Between dMMR and pMMR Subtypes of Endometrial Cancer OncLive
Published: April 2, 2024, 7 a.m.
Rubraca sheds positive light for PARP inhibitors in endometrial cancer - Clinical Trials Arena
Rubraca sheds positive light for PARP inhibitors in endometrial cancer Clinical Trials Arena
Published: April 2, 2024, 7 a.m.
LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination - Nature.com
LIN28B induced PCAT5 promotes endometrial cancer progression and glycolysis via IGF2BP3 deubiquitination Nature.com
Published: April 2, 2024, 7 a.m.
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer - Oncology Learning Network
Molecular Classification May Predict Survival Outcomes in Endometrial Cancer Oncology Learning Network
Published: April 1, 2024, 7 a.m.
Link copied to clipboard!